{"id":"NCT01099579","sponsor":"Bristol-Myers Squibb","briefTitle":"PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)","officialTitle":"A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder Boosted With Ritonavir (RTV) With an Optimized NRTI Background Therapy, in HIV Infected Pediatric Patients Greater Than or Equal to 3 Months to Less Than 6 Years. (Pediatric Atazanavir International Clinical Evaluation: the PRINCE I Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10-13","primaryCompletion":"2012-10-04","completion":"2017-09-11","firstPosted":"2010-04-07","resultsPosted":"2014-02-06","lastUpdate":"2018-05-24"},"enrollment":82,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV Infections"],"interventions":[{"type":"DRUG","name":"Atazanavir powder","otherNames":["Reyataz","BMS-232632"]},{"type":"DRUG","name":"Ritonavir oral solution","otherNames":["Norvir"]},{"type":"DRUG","name":"Atazanavir capsules","otherNames":[]},{"type":"DRUG","name":"Ritonavir capsules","otherNames":[]}],"arms":[{"label":"Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg","type":"EXPERIMENTAL"},{"label":"Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg","type":"EXPERIMENTAL"},{"label":"Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine whether atazanavir powder combined with ritonavir is safe and well tolerated and produces appropriate drug exposure in children â‰¥3 months to \\<6 years of age.","primaryOutcome":{"measure":"Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation","timeFrame":"From Day 1 to Week 48","effectByArm":[{"arm":"Atazanavir Powder, 150 mg/Ritonavir Oral Solution, 80 mg","deltaMin":0,"sd":null},{"arm":"Atazanavir Powder, 200 mg/Ritonavir Oral Solution, 80 mg","deltaMin":0,"sd":null},{"arm":"Atazanavir Powder, 250 mg/Ritonavir Oral Solution, 80 mg","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"3 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":10},"locations":{"siteCount":18,"countries":["Brazil","Chile","Mexico","Peru","South Africa","Thailand"]},"refs":{"pmids":[],"seeAlso":["http://bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":21},"commonTop":["Diarrhoea","Upper respiratory tract infection","Vomiting","Cough","Gastroenteritis"]}}